Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivekimig for moderate to severe hidradenitis suppurativa
NL-OMON60285Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of brivekimig in hidradenitis suppurativa (HS), sponsored by Sanofi. Primary endpoint: Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75). Started Jul 2026; status: recruiting.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON60285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60285.